Analysis of copy number loss of the ErbB4 receptor tyrosine kinase in glioblastoma

Current treatments for glioblastoma multiforme (GBM)—an aggressive form of brain cancer—are minimally effective and yield a median survival of 14.6 months and a two-year survival rate of 30%. Given the severity of GBM and the limitations of its treatment, there is a need for the discovery of novel d...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, DeAnalisa C., Scanteianu, Adriana, DiStefano, Matthew, Bouhaddou, Mehdi, Birtwistle, Marc R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5771580/
https://www.ncbi.nlm.nih.gov/pubmed/29342193
http://dx.doi.org/10.1371/journal.pone.0190664

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5771580/
https://www.ncbi.nlm.nih.gov/pubmed/29342193
http://dx.doi.org/10.1371/journal.pone.0190664

Ejemplares similares